Data on this page show the responses of all individuals aged 12 years and older who received the adult 30 microgram formulation of the Pfizer COVID-19 vaccine and completed an AusVaxSafety survey sent on day 3 after vaccination. Safety data for individuals aged 5-11 years who received the paediatric 10 microgram formulation of the Pfizer COVID-19 vaccine are available here. These data provide you with a profile of what to expect in the days following your Pfizer COVID-19 vaccination and can assist when planning for your COVID-19 vaccination.

Have you been diagnosed with myocarditis following COVID-19 vaccination?

Enrol in the AusVaxSafety long-term follow-up program to help Australia better understand the long-term effects of myocarditis following COVID-19 vaccination.

Click here to enrol or learn more


The profile of reported events from AusVaxSafety surveillance of the Pfizer (Comirnaty) COVID-19 vaccine is similar to that reported in clinical trials and from post-marketing surveillance overseas.

AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website.

Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here.

Links to further information on the expected profile for the Pfizer (Comirnaty) COVID-19 vaccine are available below: 

AusVaxSafety will continue to closely monitor the safety data of all COVID-19 vaccines in use in Australia in conjunction with the TGA.

Last updated August 2022